

Laura B Ramsey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/678047/laura-b-ramsey-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

2,420
citations

24
h-index

48
g-index

110
ext. papers

3,039
ext. citations

4.9
avg, IF

4.71
L-index

#	Paper	IF	Citations
91	The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	9
90	Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 833217	5.6	2
89	Pediatric Psychopharmacology for Depressive and Anxiety Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2022 , 20, 184-190	1.1	
88	Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy.. <i>Implementation Science Communications</i> , 2022 , 3, 52	2.2	0
87	Characterizing Pharmacogenetic Testing Among Children's Hospitals. <i>Clinical and Translational Science</i> , 2021 , 14, 692-701	4.9	7
86	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 1970-1970	2.2	
85	Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series. <i>Clinical and Translational Science</i> , 2021 ,	4.9	2
84	Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. <i>Pediatric Research</i> , 2021 ,	3.2	1
83	Planning and Conducting a Pharmacogenetics Association Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 688-701	6.1	1
82	The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
81	Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. <i>Clinical and Translational Science</i> , 2021 , 14, 2267-2277	4.9	1
80	Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 589-594	6.1	3
79	Sleep Disturbances in Selective Serotonin Reuptake Inhibitor-Treated Youth with Anxiety Disorders and Obsessive Compulsive Disorder-A Bayesian Hierarchical Modeling Meta-Analysis. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021 , 31, 387-388	2.9	1
78	Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies. <i>Cancers</i> , 2021 , 13,	6.6	8
77	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. <i>Genetics in Medicine</i> , 2021 , 23, 2335-2341	8.1	5
76	Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021 , 60, 660-664	7.2	5
75	CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021 , 31, 56-62	2.9	3

74	Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 179-188	6.1	9
73	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 559-562	6.1	4
72	SLCO1B1 *15 allele is associated with methotrexate-induced nausea in pediatric patients with inflammatory bowel disease. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
71	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. <i>Clinical and Translational Science</i> , 2021 ,	4.9	2
70	Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021 , 60, 1309-1318	7.2	5
69	Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors. <i>Frontiers in Pharmacology</i> , 2021 , 12, 749692	5.6	2
68	Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations. <i>Depression and Anxiety</i> , 2020 , 37, 747-759	8.4	2
67	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. <i>British Journal of Clinical Pharmacology</i> , 2020 ,	3.8	6
66	MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 635-643	6.1	13
65	The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020 , 30, 276-277	2.9	2
64	Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	16
63	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 50-52	6.1	13
62	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28040	3	22
61	PharmGKB summary: sertraline pathway, pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2020 , 30, 26-33	1.9	6
60	Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020 , 30, 267-272	2.9	2
59	Gene-Based Dose Optimization in Children. <i>Annual Review of Pharmacology and Toxicology</i> , 2020 , 60, 311-331	17.9	11
58	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. <i>JAMA Network Open</i> , 2020 , 3, e2029411	10.4	10
57	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27618	3	12

56	Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 298-301	6.1	4
55	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019 , 14, e0216328	3.7	4
54	Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019 , 29, 348-361	2.9	17
53	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. <i>Genetics in Medicine</i> , 2019 , 21, 2255-2263	8.1	38
52	Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. <i>Frontiers in Pharmacology</i> , 2019 , 10, 99	5.6	41
51	CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019 , 29, 340-347	2.9	21
50	Association of *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients. <i>ACR Open Rheumatology</i> , 2019 , 1, 58-62	3.5	11
49	Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 49-52	6.1	31
48	Thyroid Function Screening in Children and Adolescents With Mood and Anxiety Disorders. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	1
47	Racial Differences in Escitalopram/Citalopram-Related Weight Gain in Children and Adolescents: A Natural Language Processing-Based Electronic Medical Record Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019 , 29, 162-163	2.9	3
46	Screen Identifies and Other Genetic Drivers in Human B-cell Lymphoma. <i>Molecular Cancer Research</i> , 2019 , 17, 567-582	6.6	11
45	Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2018 , 48, 40-49	2.2	36
44	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , 2018 , 23, 52-61	5.7	63
43	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 2665-2665	2.2	
42	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017 , 31, 1325-1332	13.2	18
41	Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 131-140	6.1	35
40	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 294-302	1.9	11
39	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. <i>Nature Immunology</i> , 2017 , 18, 694-704	19.1	45

38	Learning Health Systems as Facilitators of Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 359-367	6.1	16
37	Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. <i>Pharmacotherapy</i> , 2017 , 37, 1172-1190	5.8	14
36	Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. <i>PLoS ONE</i> , 2016 , 11, e0151433	3.7	32
35	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016 , 127, 558-64	2.2	47
34	Effect of premedications in a murine model of asparaginase hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 541-51	4.7	12
33	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015 , 47, 607-14	36.3	96
32	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015 , 126, 69-75	2.2	54
31	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. <i>Blood</i> , 2015 , 126, 3714-3714	2.2	2
30	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015 , 10, e0135134	3.7	13
29	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 250-250	2.2	
28	Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2014 , 50, 2685-94	7.5	56
27	The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 423-8	6.1	284
26	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014 , 124, 1266-76	2.2	70
25	A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required. <i>Frontiers in Genetics</i> , 2014 , 5, 323	4.5	9
24	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 263-71	1.9	8
23	A Murine Model of Asparaginase Allergy. <i>Blood</i> , 2014 , 124, 2295-2295	2.2	
22	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014 , 124, 63-63	2.2	
21	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 3701-3701	2.2	1

20	Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. <i>Cell Reports</i> , 2013 , 5, 1047-59	10.6	98
19	Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 126-30	3.1	18
18	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013 , 121, 898-904	2.2	137
17	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 60-60	2.2	1
16	Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 360-5	6.1	40
15	The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 112-7	6.1	254
14	IL-7 functionally segregates the pro-B cell stage by regulating transcription of recombination mediators across cell cycle. <i>Journal of Immunology</i> , 2012 , 188, 6084-92	5.3	32
13	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. <i>Human Molecular Genetics</i> , 2012 , 21, 4793-804	5.6	47
12	Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. <i>Genome Research</i> , 2012 , 22, 1-8	9.7	177
11	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012 , 120, 2466-2466	2.2	1
10	Substrain-specific differences in survival and osteonecrosis incidence in a mouse model. <i>Comparative Medicine</i> , 2012 , 62, 466-71	1.6	15
9	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 530-530	2.2	1
8	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. <i>Blood</i> , 2012 , 120, 3560-3560	2.2	
7	Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1135-49	16.6	114
6	Functional characterization of liver enhancers that regulate drug-associated transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 571-8	6.1	24
5	Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways. <i>Immunology Letters</i> , 2011 , 135, 74-7	4.1	9
4	Ebf1orPax5haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. <i>Journal of Cell Biology</i> , 2011 , 193, i13-i13	7.3	
3	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. <i>Blood</i> , 2011 , 118, 571-571	2.2	

- | | | | |
|---|--|------|-----|
| 2 | RAG-1 and ATM coordinate monoallelic recombination and nuclear positioning of immunoglobulin loci. <i>Nature Immunology</i> , 2009 , 10, 655-64 | 19.1 | 114 |
| 1 | B cell receptor basal signaling regulates antigen-induced Ig light chain rearrangements. <i>Journal of Immunology</i> , 2008 , 180, 4728-41 | 53 | 34 |